Company Description
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States.
The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process.
In addition, it offers Lumin Bioinformatics, a dynamic analytic and visualization software that empowers cancer biologists to harness the power of computational science in a convenient and sophisticated tool.
The company markets its products through internet, word of mouth, and sales force to patients and physicians.
Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.
The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
| Country | United States |
| IPO Date | Mar 25, 1986 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 230 |
| CEO | Dr. Ronnie Morris M.D. |
Contact Details
Address: 855 N. Wolfe Street, Suite 619 Baltimore, Maryland 21205 United States | |
| Phone | 410-369-0365 |
| Website | championsoncology.com |
Stock Details
| Ticker Symbol | CSBR |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0000771856 |
| CUSIP Number | 15870P307 |
| ISIN Number | US15870P3073 |
| Employer ID | 52-1401755 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ronnie Morris M.D. | Chief Executive Officer and Director |
| David Barry Miller M.B.A. | Chief Financial Officer |
| Brady Davis | President |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer |
| Arthur Hanson | Vice President of Technology |
| Rachel A. Bunting M.B.A., M.S., MBA, MS | Vice President of Global Marketing |
| David DeOrnellis BS, CMAR, CPIA, RLATG | Executive Vice President of Global Laboratory Operations |
| Dr. Michael Ritchie M.B.A., Ph.D. | Chief Commercial Officer |
| Dr. Karin Abarca Heidemann Ph.D. | Executive Vice President of Global Scientific Operations |
| Dr. Marianna Zipeto Ph.D. | Executive Vice President of Commercial, Research Services and Partnering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 15, 2024 | 10-Q | Quarterly Report |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 13, 2023 | 10-Q | Quarterly Report |
| Dec 12, 2023 | 8-K | Current Report |
| Oct 19, 2023 | 8-K | Current Report |
| Oct 17, 2023 | 8-K | Current Report |
| Sep 13, 2023 | 10-Q | Quarterly Report |
| Sep 13, 2023 | 8-K | Current Report |
| Aug 28, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |